Tesla typically reports numbers shortly after the close. The stock typically moves on headline results. The stock continues to fluctuate in after-hours trading while investors and analysts pore over the new figures until the earnings conference call, which starts at 5:30 p.
Tesla typically reports numbers shortly after the close. The stock typically moves on headline results. The stock continues to fluctuate in after-hours trading while investors and analysts pore over the new figures until the earnings conference call, which starts at 5:30 p.
Best Buy on Wednesday announced CEO Corie Barry will step down after seven years leading the company to be replaced by chief customer, product and fulfillment officer Jason Bonfig.
Best Buy on Wednesday announced CEO Corie Barry will step down after seven years leading the company to be replaced by chief customer, product and fulfillment officer Jason Bonfig.
murat4art United Airlines Holdings ( UAL ) traded lower after cutting its profit outlook amid the recent surge in jet fuel prices. Despite being the carrier most in focus this earnings cycle, UAL ranks only fifth among U.S. passenger airline stocks on Seeking Alpha's Quant Rating system, sitting behind not just the two Buy-rated names, but also rivals Delta ( DAL ) and JetBlue ( JBLU ), each of wh...
murat4art United Airlines Holdings ( UAL ) traded lower after cutting its profit outlook amid the recent surge in jet fuel prices. Despite being the carrier most in focus this earnings cycle, UAL ranks only fifth among U.S. passenger airline stocks on Seeking Alpha's Quant Rating system, sitting behind not just the two Buy-rated names, but also rivals Delta ( DAL ) and JetBlue ( JBLU ), each of which edges it out by a thin margin. With a Hold rating of 3.09, UAL's quant profile reflects the tension between its strong operational execution and the overhang of elevated fuel costs and compressed forward earnings estimates. Topping the Quant rankings are American Airlines ( AAL ) and Southwest Airlines ( LUV ), the only two carriers currently receiving bullish assessments with scores of 4.31 and 4.12, respectively. Delta ( DAL ) and JetBlue ( JBLU ) trail with Hold ratings of 3.12 and 3.10, just ahead of UAL's 3.09. SkyWest ( SKYW ) and Alaska Air Group ( ALK ) round out the list with scores of 2.95 and 2.90, edging closer to bearish territory. Seeking Alpha's Quant system grades stocks based on valuation, growth, stock momentum, and profitability on a scale of 1 to 5. Scores above 3.5 indicate a bullish rating; 2.5 or below signals a bearish profile. Here is the list: American Airlines Group Inc. ( AAL ), Quant Rating: 4.31 Southwest Airlines Co. ( LUV ), Quant Rating: 4.12 Delta Air Lines, Inc. ( DAL ), Quant Rating: 3.12 JetBlue Airways Corporation ( JBLU ), Quant Rating: 3.10 United Airlines Holdings, Inc. ( UAL ), Quant Rating: 3.09 SkyWest, Inc. ( SKYW ), Quant Rating: 2.95 Alaska Air Group, Inc. ( ALK ), Quant Rating: 2.90 More on passenger airlines Alaska Air Group, Inc. (ALK) Q1 2026 Earnings Call Transcript Alaska Air Group, Inc. 2026 Q1 - Results - Earnings Call Presentation JetBlue: A Risky Bet In A Fragile Sky United Airlines' guidance spooks Wall Street despite outlook to recover fuel spikes -- analysts Delta and United benefit from competitors cutting cap...
Barbara Humpton, CEO of USA Rare Earth, joins Dani Burger on "Bloomberg Deals." USA Rare Earth agreed to acquire Brazil’s Serra Verde Group in a $2.8 billion cash-and-stock transaction, marking one of the largest deals in the rare-earths industry. (Source: Bloomberg)
Barbara Humpton, CEO of USA Rare Earth, joins Dani Burger on "Bloomberg Deals." USA Rare Earth agreed to acquire Brazil’s Serra Verde Group in a $2.8 billion cash-and-stock transaction, marking one of the largest deals in the rare-earths industry. (Source: Bloomberg)
koya79/iStock via Getty Images Investment Overview Altimmune ( ALT ) is a Gaithersburg, Maryland based biotech that I have been following for several years, primarily due to its lead drug candidate pemvidutide, a glucagon/GLP-1 dual receptor agonist - not dissimilar in terms of mechanism of action ("MoA") to the wildly successful drug molecules semaglutide and tirzepatide, better known as Wegovy/O...
koya79/iStock via Getty Images Investment Overview Altimmune ( ALT ) is a Gaithersburg, Maryland based biotech that I have been following for several years, primarily due to its lead drug candidate pemvidutide, a glucagon/GLP-1 dual receptor agonist - not dissimilar in terms of mechanism of action ("MoA") to the wildly successful drug molecules semaglutide and tirzepatide, better known as Wegovy/Ozempic and Zepbound/Mounjaro, in the indications of obesity/Type 2 Diabetes ("T2D"), and marketed and sold by Novo Nordisk ( NVO )/Eli Lilly ( LLY ), earning combined revenues of >$65bn in 2025. My first take on Altimmune was a negative one - in February 2024, I gave Altimmune stock a Sell rating in a note for Seeking Alpha, which has ultimately proven the right call, as stock has fallen in value by >70% since. I noted in that post that: At the end of November 2023 - the same month in which Zepbound was approved - Altimmune shared 48-week data from its Momentum study, this time revealing mean weight loss of 15.6% at the 2.4mg dose, and that >30% of subjects achieved >20% weight loss on the higher 2.4 mg dose at 48 weeks. in December, analysts at JMP Securities wrote that: Pemvidutide has a competitive profile based on the top-line MOMENTUM data with greater weight loss than semaglutide, better lipid changes and tolerability than tirzepatide, and better cardiac safety than retatrutide." Altimmune rose to a value of $12 per share in January 2024, but it has not traded higher since, and the company is no longer even evaluating pemvidutide as an obesity therapy - instead it has pivoted into studies in metabolic dysfunction-associated steatohepatitis (“MASH”), alcohol use disorder ("AUD"), and alcohol associated liver disease ("ALD"). My sell thesis was based around Altimmune's data not being quite strong enough to break the duopoly of semaglutide/tirzepatide, its efficacy seemingly falling slightly below these two molecules, with a higher rate of study discontinuations - ~20% i...
Key PointsMy Personal CFO reduced its Stagwell stake by 500,882 shares in the first quarter; the estimated trade size was $2.80 million based on quarterly average prices.
Key PointsMy Personal CFO reduced its Stagwell stake by 500,882 shares in the first quarter; the estimated trade size was $2.80 million based on quarterly average prices.
A former employee of Jimmy "MrBeast" Donaldson has filed a lawsuit alleging that she faced "intentional infliction of emotional distress" from harassment at the YouTuber's production company, was asked to work during maternity leave, and was wrongfully fired just a few weeks after returning from leave. According to the lawsuit, plaintiff Lorrayne Mavromatis and other female employees were demeaned...
A former employee of Jimmy "MrBeast" Donaldson has filed a lawsuit alleging that she faced "intentional infliction of emotional distress" from harassment at the YouTuber's production company, was asked to work during maternity leave, and was wrongfully fired just a few weeks after returning from leave. According to the lawsuit, plaintiff Lorrayne Mavromatis and other female employees were demeaned by their male colleagues, who perpetuated a toxic, "male-centric workplace." Mavromatis was one of the few women in the executive suite at Beast Industries before she was fired. The lawsuit claims that she faced unwanted sexual advances and comme … Read the full story at The Verge.
The move, which could open up medical research on cannabis as well as banking services for growers, follows an executive order to reclassify the substance in December.
The move, which could open up medical research on cannabis as well as banking services for growers, follows an executive order to reclassify the substance in December.
Software maker Vast Data has raised a $1 billion Series F, tripling its valuation to $30 billion. Vast Data CEO Renen Hallak says the company is readying itself for an IPO. Hallak joins Caroline Hyde and Ed Ludlow on “Bloomberg Tech.” (Source: Bloomberg)
Software maker Vast Data has raised a $1 billion Series F, tripling its valuation to $30 billion. Vast Data CEO Renen Hallak says the company is readying itself for an IPO. Hallak joins Caroline Hyde and Ed Ludlow on “Bloomberg Tech.” (Source: Bloomberg)
Key PointsFund acquired 43,072 shares of J.P. Morgan Exchange-Traded Fund Trust - JPMorgan International Value ETF; estimated transaction value $3.72 million based on quarterly average pricing.
Key PointsFund acquired 43,072 shares of J.P. Morgan Exchange-Traded Fund Trust - JPMorgan International Value ETF; estimated transaction value $3.72 million based on quarterly average pricing.
Love Employee/iStock via Getty Images 2026 2026 Annualized as of March 31, 2026 Annualized as of March 31, 2026 Annualized as of March 31, 2026 Annualized as of March 31, 2026 Annualized as of March 31, 2026 YTD Q1 1 Yr 3 Yrs 5 Yrs 10 Yrs Since 6/30/1984 Polaris Intl. Equity Composite (net of fees) 5.13% 5.13% 34.62% 16.92% 8.03% 8.87% 10.44% Polaris Intl. Equity Composite (gross of fees) 5.26% 5....
Love Employee/iStock via Getty Images 2026 2026 Annualized as of March 31, 2026 Annualized as of March 31, 2026 Annualized as of March 31, 2026 Annualized as of March 31, 2026 Annualized as of March 31, 2026 YTD Q1 1 Yr 3 Yrs 5 Yrs 10 Yrs Since 6/30/1984 Polaris Intl. Equity Composite (net of fees) 5.13% 5.13% 34.62% 16.92% 8.03% 8.87% 10.44% Polaris Intl. Equity Composite (gross of fees) 5.26% 5.26% 35.33% 17.51% 8.57% 9.44% 11.24% MSCI EAFE Index, gross dividends reinvested -1.12% -1.12% 21.88% 14.18% 8.45% 8.91% 8.95% Click to enlarge Composite returns are preliminary. Past performance is not indicative of future results. 2026 started out well, with global growth tracking slightly above expectations. The U.S. Federal Reserve held its benchmark rate at 3.5%–3.75% following a December cut, and several other G20 central banks maintained or reduced rates, creating a broadly supportive macro backdrop through January and February. Cyclicals drove strong early returns, even as U.S. tariff threats continued. March brought a decisive turn. The war in Iran and the closure of the Strait of Hormuz sent energy prices sharply higher. Both the European Central Bank and Bank of Japan held rates steady but cautioned that the ongoing conflict poses risks of rising inflation and slowing economic growth. The pivot reshuffled sector leadership — lifting energy and defensive positions while tamping down AI-adjacent cyclicals. On this backdrop, the Polaris International Equity Composite gained 5.13% (net of fees), outperforming the MSCI EAFE Index, which returned -1.12%. The Composite outperformed in most sectors including double-digit gains from materials, energy and utilities, while information technology and health care added measurably. Absolute detractors included consumer discretionary, industrials and communication services. Holdings in Norway, Italy, Japan Spain and the Netherlands contributed most, along with off-benchmark countries including Canada and South Korea. China decl...